Answers are grounded in this paper and cite their sources.
Decisions for individualized therapies in patients with brain metastasis are often made from primary-tumor biopsies. We demonstrate that clinically actionable alterations present in brain metastases are frequently not detected in primary biopsies, suggesting that sequencing of primary biopsies alone may miss a substantial number of opportunities for targeted therapy.
No takes yet. Share an insight, caveat, or question.
Brastianos et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: